Eyepoint Pharmaceuticals (EYPT) Given New $6.00 Price Target at B. Riley

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target hoisted by B. Riley from $5.00 to $6.00 in a research note published on Tuesday. They currently have a buy rating on the stock. B. Riley also issued estimates for Eyepoint Pharmaceuticals’ FY2020 earnings at ($0.23) EPS, FY2021 earnings at ($0.11) EPS, FY2022 earnings at $0.06 EPS and FY2023 earnings at $0.26 EPS.

Several other equities research analysts also recently issued reports on the company. HC Wainwright restated a buy rating and set a $4.50 price objective on shares of Eyepoint Pharmaceuticals in a report on Monday, October 1st. ValuEngine upgraded Eyepoint Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, September 19th. Finally, Zacks Investment Research downgraded Eyepoint Pharmaceuticals from a hold rating to a sell rating in a report on Monday, September 17th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Eyepoint Pharmaceuticals currently has an average rating of Buy and a consensus price target of $5.40.

EYPT stock opened at $2.65 on Tuesday. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 1.48. Eyepoint Pharmaceuticals has a 52-week low of $0.93 and a 52-week high of $3.94. The company has a market cap of $159.39 million, a price-to-earnings ratio of -4.57 and a beta of 0.85.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, September 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 301.45% and a negative net margin of 1,795.71%. The business had revenue of $0.72 million for the quarter, compared to analysts’ expectations of $0.67 million. On average, equities analysts forecast that Eyepoint Pharmaceuticals will post -0.42 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Essex Investment Management Co. LLC grew its position in shares of Eyepoint Pharmaceuticals by 65.0% in the 3rd quarter. Essex Investment Management Co. LLC now owns 134,509 shares of the company’s stock worth $480,000 after acquiring an additional 52,977 shares in the last quarter. Northern Trust Corp acquired a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth approximately $218,000. California Public Employees Retirement System acquired a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth approximately $135,000. Bard Associates Inc. acquired a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth approximately $189,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth approximately $2,339,000. Institutional investors own 62.90% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.

Featured Article: Stock Symbols and CUSIP Explained

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply